Literature DB >> 22983708

Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism.

Stéphane J Baudouin1, Julien Gaudias, Stefan Gerharz, Laetitia Hatstatt, Kuikui Zhou, Pradeep Punnakkal, Kenji F Tanaka, Will Spooren, Rene Hen, Chris I De Zeeuw, Kaspar Vogt, Peter Scheiffele.   

Abstract

The genetic heterogeneity of autism poses a major challenge for identifying mechanism-based treatments. A number of rare mutations are associated with autism, and it is unclear whether these result in common neuronal alterations. Monogenic syndromes, such as fragile X, include autism as one of their multifaceted symptoms and have revealed specific defects in synaptic plasticity. We discovered an unexpected convergence of synaptic pathophysiology in a nonsyndromic form of autism with those in fragile X syndrome. Neuroligin-3 knockout mice (a model for nonsyndromic autism) exhibited disrupted heterosynaptic competition and perturbed metabotropic glutamate receptor-dependent synaptic plasticity, a hallmark of fragile X. These phenotypes could be rescued by reexpression of neuroligin-3 in juvenile mice, highlighting the possibility of reverting neuronal circuit alterations in autism after the completion of development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983708     DOI: 10.1126/science.1224159

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  139 in total

1.  PICK1 mediates synaptic recruitment of AMPA receptors at neurexin-induced postsynaptic sites.

Authors:  Junyu Xu; Chuen Kam; Jian-Hong Luo; Jun Xia
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

Review 2.  Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders.

Authors:  Mustafa Sahin; Mriganka Sur
Journal:  Science       Date:  2015-10-15       Impact factor: 47.728

3.  The Sorting Receptor SorCS1 Regulates Trafficking of Neurexin and AMPA Receptors.

Authors:  Jeffrey N Savas; Luís F Ribeiro; Keimpe D Wierda; Rebecca Wright; Laura A DeNardo-Wilke; Heather C Rice; Ingrid Chamma; Yi-Zhi Wang; Roland Zemla; Mathieu Lavallée-Adam; Kristel M Vennekens; Matthew L O'Sullivan; Joseph K Antonios; Elizabeth A Hall; Olivier Thoumine; Alan D Attie; John R Yates; Anirvan Ghosh; Joris de Wit
Journal:  Neuron       Date:  2015-08-19       Impact factor: 17.173

Review 4.  From the genetic architecture to synaptic plasticity in autism spectrum disorder.

Authors:  Thomas Bourgeron
Journal:  Nat Rev Neurosci       Date:  2015-09       Impact factor: 34.870

Review 5.  Local and long-range circuit elements for cerebellar function.

Authors:  Le Xiao; Peter Scheiffele
Journal:  Curr Opin Neurobiol       Date:  2018-01-06       Impact factor: 6.627

Review 6.  Use of transcranial magnetic stimulation in autism spectrum disorders.

Authors:  Lindsay M Oberman; Alexander Rotenberg; Alvaro Pascual-Leone
Journal:  J Autism Dev Disord       Date:  2015-02

Review 7.  Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives.

Authors:  Martien J Kas; Jeffrey C Glennon; Jan Buitelaar; Elodie Ey; Barbara Biemans; Jacqueline Crawley; Robert H Ring; Clara Lajonchere; Frederic Esclassan; John Talpos; Lucas P J J Noldus; J Peter H Burbach; Thomas Steckler
Journal:  Psychopharmacology (Berl)       Date:  2013-09-19       Impact factor: 4.530

Review 8.  LTD-like molecular pathways in developmental synaptic pruning.

Authors:  Claire Piochon; Masanobu Kano; Christian Hansel
Journal:  Nat Neurosci       Date:  2016-09-27       Impact factor: 24.884

Review 9.  Advancing the discovery of medications for autism spectrum disorder using new technologies to reveal social brain circuitry in rodents.

Authors:  Martien J Kas; Meera E Modi; Michael D Saxe; Daniel G Smith
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

Review 10.  Gephyrin: a master regulator of neuronal function?

Authors:  Shiva K Tyagarajan; Jean-Marc Fritschy
Journal:  Nat Rev Neurosci       Date:  2014-03       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.